Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

Abstract

A Corrigendum on: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial by Sun, C., Lu, B., Liu, Y., Zhang, Y., Wei, H., Hu, X., Hu, P., Zhao, Q., Liu, Y., Ye, K., Wang, K., Gu, Z., Liu, Z., Ye, J., Zhang, H., Zhu, H., Jiang, Z., Liu, Y., Wan, N., Yan, C., Yin, J., Ying, L., Huang, F., Yin, Q., Xi, L., Luo, F. and Cheng, R. (2021) Front. Endocrinol. 12:779365. doi: 10.3389/fendo.2021.779365 The second and third authors, Biao Lu and Yu Liu, were not listed as co-first-authors in the article as published originally. The Author Contributions statement, published originally read “FL and RC conceived the study design, managed the study, conducted the data analysis, and wrote the manuscript. CS helped with the data analysis and editing of the manuscript. LX, BL, YL, YZ, HW, XH, PH, QZ, YLL, KY, KW, ZG, ZL, JY, HXZ, HZ, ZJ, YJL, NW, CY, JYY, LY, FH, and QY are site investigators and conducted the study in each participating center. All authors contributed to the article and approved the submitted version”. The corrected Author Contributions statement is as follows: “FL and RC conceived the study design, managed the study, conducted the data analysis, and wrote the manuscript. CS helped with the data analysis and editing of the manuscript. BL and YL contributed to the design of the study protocol, training of trial investigators. LX, BL, YL, YZ, HW, XH, PH, QZ, YLL, KY, KW, ZG, ZL, JY, HXZ, HZ, ZJ, YJL, NW, CY, JYY, LY, FH, and QY are site investigators and conducted the study in each participating center. All authors contributed to the article and approved the submitted version.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Keywords: growth hormone deficiency, PEGylated recombinant human growth hormone, PEG-rhGH, IGF-2, children Citation: Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F and Cheng R (2021) Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial. Front. Endocrinol. 12:830469. doi: 10.3389/fendo.2021.830469 Received: 07 December 2021; Accepted: 09 December 2021; Published: 28 December 2021. Approved by: Copyright © 2021 Sun, Lu, Liu, Zhang, Wei, Hu, Hu, Zhao, Liu, Ye, Wang, Gu, Liu, Ye, Zhang, Zhu, Jiang, Liu, Wan, Yan, Yin, Ying, Huang, Yin, Xi, Luo and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Feihong Luo, luofh@fudan.edu.cn; Ruoqian Cheng, chengrq78@163.com ^†These authors have contributed equally to this work and share first authorship